19134-50-0

Basic information

• Product Name: 1-phenyl-2-pyrrolidin-1-yl-propan-1-one
• Synonyms: 1-phenyl-2-pyrrolidin-1-yl-propan-1-one;Alpha-PBP;appp a-ppp bk-mdea CAS NO.19134-50-0;appp a-ppp bk-mdea;appp a-ppp bk-mdea a-ppp;low price high quality appp a-ppp;Pharmaceutical intermediates appp APPP;low price high quality appp a-ppp a-ppp
• CAS NO: 19134-50-0
• Molecular Formula: C₁₃H₁₇NO
• Molecular Weight: 203.28
• Product Categories: Pharmaceutical Intermediates;Chemical and pharmaceutical intermediates
• Mol File: 19134-50-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 309.708 °C at 760 mmHg
• Flash Point: 110.565 °C
• Appearance: /
• Density: 1.063 g/cm³
• Vapor Pressure: 0.000628mmHg at 25°C
• Refractive Index: 1.548
• PKA: 8.49±0.20(Predicted)
• CAS DataBase Reference: 1-phenyl-2-pyrrolidin-1-yl-propan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-phenyl-2-pyrrolidin-1-yl-propan-1-one(19134-50-0)
• EPA Substance Registry System: 1-phenyl-2-pyrrolidin-1-yl-propan-1-one(19134-50-0)

Safety Data

• Hazardous Substances Data: 19134-50-0(Hazardous Substances Data)

Usage

Description

1-phenyl-2-pyrrolidin-1-yl-propan-1-one, also known as α-Pyrrolidinopropiophenone, is a chiral cathinone derivative with structural similarities to the appetite suppressant Diethylpropion. It is recognized for its stimulant properties and is classified as a controlled substance due to its potential for misuse and health risks.

Uses

Used in Pharmaceutical Research:
1-phenyl-2-pyrrolidin-1-yl-propan-1-one is used as a research compound for understanding the effects of stimulant drugs on the central nervous system. Its structural similarity to other stimulants allows scientists to study its pharmacological properties and potential applications in the development of new medications.
Used in Drug Enforcement and Control:
As a controlled substance, 1-phenyl-2-pyrrolidin-1-yl-propan-1-one is used in the context of drug enforcement and control to monitor and regulate its distribution, sale, and use. This helps to prevent misuse and ensure that the substance is only used for legitimate medical or research purposes.
Please note that the provided materials do not mention any specific industrial applications for 1-phenyl-2-pyrrolidin-1-yl-propan-1-one. The information given focuses on its status as a controlled substance and its use in pharmaceutical research.

InChI:InChI=1/C13H17NO/c1-11(14-9-5-6-10-14)13(15)12-7-3-2-4-8-12/h2-4,7-8,11H,5-6,9-10H2,1H3

Upstream product

• 123-75-1 pyrrolidine 
• 2114-00-3 2-bromo-1-phenyl-1-propanone 
• 19733-68-7 N-chloropyrrolidine 
• 93-55-0 1-phenyl-propan-1-one 
• 93-54-9 1-Phenyl-1-propanol 
• 108-86-1 bromobenzene 
• 173676-57-8 1-phenyl-2-(pyrrolidin-1-yl)propan-1-ol 
• 637-50-3 1-phenylpropene 

Downstream Products

• 99318-85-1 1,1-diphenyl-2-pyrrolidino-propan-1-ol 
• 1215194-08-3 (S)-(-)-1-phenyl-2-(1-pyrrolidinyl)-1-propanone 
• 1215194-07-2 (R)-(+)-1-phenyl-2-(1-pyrrolidinyl)-1-propanone 
• 56571-91-6 (1S,2R)-(+)-1-phenyl-2-(1-pyrrolidinyl)-1-propanol 
• 56571-91-6 (1R,2S)-1-phenyl-2-(1-pyrrolidinyl)-1-propanol 
• 92040-10-3 (SR)-(+/-)-1-phenyl-2-(1-pyrrolidinyl)-1-propanone hydrochloride 

Relevant articles and documents

α-PPP and its derivatives are selective partial releasers at the human norepinephrine transporter: A pharmacological characterization of interactions between pyrrolidinopropiophenones and uptake1 and uptake2 monoamine transporters

While classical cathinones, such as methcathinone, have been shown to be monoamine releasing agents at human monoamine transporters, the subgroup of α-pyrrolidinophenones has thus far solely been characterized as monoamine transporter reuptake inhibitors. Herein, we report data from previously undescribed α-pyrrolidinopropiophenone (α-PPP) derivatives and compare them with the pharmacologically well-researched α-PVP (α-pyrrolidinovalerophenone). Radiotracer-based in vitro uptake inhibition assays in HEK293 cells show that the investigated α-PPP derivatives inhibit the human high-affinity transporters of dopamine (hDAT) and norepinephrine (hNET) in the low micromolar range, with α-PVP being ten times more potent. Similar to α-PVP, no relevant pharmacological activity was found at the human serotonin transporter (hSERT). Unexpectedly, radiotracer-based in vitro release assays reveal α-PPP, MDPPP and 3Br-PPP, but not α-PVP, to be partial releasing agents at hNET (EC50 values in the low micromolar range). Furthermore, uptake inhibition assays at low-affinity monoamine transporters, i.e., the human organic cation transporters (hOCT) 1–3 and human plasma membrane monoamine transporter (hPMAT), bring to light that all compounds inhibit hOCT1 and 2 (IC50 values in the low micromolar range) while less potently interacting with hPMAT and hOCT3. In conclusion, this study describes (i) three new hybrid compounds that efficaciously block hDAT while being partial releasers at hNET, and (ii) highlights the interactions of α-PPP-derivatives with low-affinity monoamine transporters, giving impetus to further studies investigating the interaction of drugs of abuse with OCT1-3 and PMAT.

Preparation method of (1R,2S)-1-phenyl-2-(1-pyrrolidyl)-1-propanol

The invention discloses a preparation method of (1R,2S)-1-phenyl-2-(1-pyrrolidyl)-1-propanol. According to the preparation method, DL-1-phenyl-2-(1-pyrrolidyl)-1-acetone is taken as a starting material and subjected to resolution, racemization and reduction, and (1R,2S)-1-phenyl-2-(1-pyrrolidyl)-1-propanol is prepared. The yield of one-time resolution is higher than 35%, a resolving agent is easy to recover, and the recovery rate is higher than 90%; the racemization process is performed under the slightly alkaline condition, and the racemization yield is higher; the yield of (1R,2S)-1-phenyl-2-(1-pyrrolidyl)-1-propanol obtained through reduction is higher than 85%. The preparation method has the advantages of mild reaction conditions, stable process, high product optical purity, low cost, high production safety and the like.

NOVEL PROCESS FOR PREPARATION OF OPTICALLY PURE NOREPHEDRINE AND ITS DERIVATIVES

The present invention relates to a novel process for preparation of norephedrine and its derivatives. The present invention also relates to a process for separation of individual isomers of norephedrine and its derivatives using suitable chiral resoluting agents.